Scotiabank initiated coverage of Ocular Therapeutix with an Outperform rating and $22 price target Long-acting implants are set to revolutionize the wet AMD treatment landscape in the coming years, says the firm, which views Ocular’s Axpaxli as differentiated on efficacy and treatment durability based on previous clinical data. Management has a positive track record in the retinal space, giving the firm confidence in execution of the pivotal program that is currently enrolling, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix management to meet with Piper Sandler
- Ocular announces accelerated timelines for SOL-1 registrational trial
- Ocular Therapeutix Expands Stock Incentive Plan for Employees
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Ocular Therapeutix Appoints Donald Notman as COO
Questions or Comments about the article? Write to editor@tipranks.com